bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
092-10-0025

Order Name:
APOE Genotype (Risk for Alzheimer Disease)

 
Useful For:
Identifying patients who may be at risk for altered cholesterol metabolism and transportation. This event has associated with increase the risk for Alzheimer disease.
 
Methodology:
Real-time PCR
 
Test List In Profile:
APOE Alleles e2, e3 and e4
 
AliasesName:
Apolipoprotein E genotyping,
APOE
Alzheimer 
 
 
 
Test Code:
092-10-0025

Order Name:
APOE Genotype (Risk for Alzheimer Disease)

 
Collection Specimen Or Container:
Blood/ K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube
 
Specimen Testing Type:
Whole blood, K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube, minimum volume 1.5 ml
 
Sub Mission Container:
K3 EDTA (K3E) (Lavender Top)
 
Rejection Criteria:
Use heparin as anticoagulant.
Severe clotted specimen.
 
Specimen Stabillity:
Specimen Type Temperature Time
EDTA whole blood Refrigerated, 2oC to 8oC 7 days
 
 
 
Test Code:
092-10-0025

Order Name:
APOE Genotype (Risk for Alzheimer Disease)

 
Method detail:
Real-time PCR
 
Turnaround Time:
Reported within 7-10 days
 
Performing Location:
Clinical Genomics Tel. 14252
 
Specimen Retention Time:
3 months
 
 
 
Test Code:
092-10-0025

Order Name:
APOE Genotype (Risk for Alzheimer Disease)

 
 
Clinical Information:
Apolipoprotein E (ApoE) locates on 19q13.2 and consists of 299 amino in length. It plays an important role in cholesterol transportation and metabolism. Three most common alleles of ApoE are e3 (Cys112/Arg158), e2(Cys112/Cys158) and e4(Arg112/Arg158). Among these three alleles, e3 is the wildtype and most commonly found. Among these three alleles, ApoE3 is the wildtype and most commonly found. Mutation in ApoE might increase or decrease the risk for Alzheimer’s disease. Individuals with APOE e3/e4 genotype have a three-to-four-fold relative risk while individuals with APOE e4/e4 genotype have a 15-fold relative risk compared to those with the APOE e3/e3 genotype. Other than the risk at Late-onset Alzheimer developing, these mutations are related with the age of onset for the disease. The average age of developing Late-onset Alzheimer is 68 years at 94% for HomozygyousE4, 76 years at 47% frequency for hetrozygousE4 and 84 years at 20% frequency for those who do not carry E4.
 
Reference Value:
Wild-type of APOE gene (e3/e3)
 
Clinical Reference:
  1. Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011 Jun;13(6):597-605.
  2. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016 May;18(5):421-30.
  3. Li Z, Shue F, Zhao N, et al. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener. 2020 Nov 4;15(1):63.